| pertuzumab versus placebo | |||
| Aphinity, NCT01358877 | versus | people with operable HER2-positive eBC | double-blind |
| trastuzumab versus control | |||
| NSABP B31, 2005 | 52 weeks of trastuzumab versus no trastuzumab | patients with node-positive, HER2-positive breast cancer | |
| BCIRG006, 2013 | versus | ||
| Buzdar, 2005 | simultaneous weekly trastuzumab for 24 weeks versus no trastuzumab | patienst with HER 2-positive operable breast cancer | |
| FinHer, 2006 | concomitant treatment with trastuzumab versus no trastuzumab | Women with tumors that overexpressed HER2/neu | |
| HERA, 2005 | ??? versus ??? | patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy | |
| N9831, 2005 | versus | ||
| NOAH, 2010 | 1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment versus no trastuzumab | patients with HER2-positive locally advanced breast cancer | |
| PACS-04, 2009 | versus | ||
| N9831 (1), 0 | versus | ||
| N9831 (2), 0 | versus | ||
| FinHer (1), 3000 | versus | ||
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
